Regulus Therapeutics has appointed Douglas Williams to its board of directors.
Williams is currently executive vice president of research and development at Biogen Idec, a Regulus collaborator that recently purchased a $5 million convertible note from the firm.
Concurrent with Williams' appointment, Regulus said that directors Barry Greene and Stanley Crooke have stepped down. Greene is president and COO of Alnylam Pharmaceuticals and Crooke is chairman and CEO of Isis Pharmaceuticals, which created Regulus as a joint venture.
Rosetta Genomics has appointed Yitzhak Peterburg to its board of directors.
Peterburg has served on the boards of Teva Pharmaceuticals, and was president and CEO of Cellcom.